We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) yesterday recommended granting Gilead Sciences’ remdesivir a conditional marketing authorization as a COVID-19 treatment. Read More
Demand for the corticosteroid dexamethasone has skyrocketed in the days since the University of Oxford published trial results suggesting the drug could be a game-changer for treating severely ill COVID-19 patients, hospital data shows. Read More
Public Citizen has petitioned the FDA to require a black box warning for sodium-glucose cotransporter-2 (SGLT2) inhibitors used off-label for treatment of type 1 diabetes. Read More
New York-based BrainStorm Cell Therapeutics is launching a phase 2 trial of an investigational stem cell treatment for Alzheimer’s disease, using cells derived from patients’ bone marrow. Read More
Senior Democrats in the House unveiled a bill yesterday that would give HHS the authority to negotiate prices for hundreds of drugs and would tax noncompliant drugmakers up to 95 percent of their sales. Read More
Fulcrum Therapeutics has begun a phase 3 clinical trial in the U.S. of its investigational anti-inflammatory drug losmapimod for the treatment of hospitalized COVID-19 patients. Read More